Abstract: This invention relates to novel compositions comprising as an active ingredient one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus Vaccinium, wherein said plant(s) is/are grown under the following conditions: a. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and; b. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity. More particularly, said plant(s) is/are optionally grown at least 7 days past maturity. Further, the compositions of the inventive subject matter optionally may include an additional element comprising an oil from Oncorhynchus species. Further, said compositions may be employed to treat a variety of diseases, disorders, and conditions, as described herein.

Abstract: This invention relates to novel compositions comprising as an active ingredient one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus Vaccinium, wherein said plant(s) is/are grown under the following conditions: (a). Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and; (b). Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity. More particularly, said plant(s) is/are optionally grown at least 7 days past maturity. Further, the compositions of the inventive subject matter optionally may include an additional element comprising an oil from Oncorhynchus species. Further, said compositions may be employed to treat a variety of diseases, disorders, and conditions, as described herein.

Abstract: This invention relates to novel compositions comprising as an active ingredient one or more berries, leaves, roots, and/or root barks obtained from one or more plant species of the genus Vaccinium, wherein said plant(s) is/are grown under the following conditions: a. Subject to one or more uninterrupted photoperiod(s) of at least about 18 hours to 24 hours per day for about 60 days during flowering and fruit setting; and; b. Subject to one or more uninterrupted photoperiod(s) of at least about 15 hours per day for about 30 days during fruit ripening and maturity. More particularly, said plant(s) is/are optionally grown at least 7 days past maturity. Further, the compositions of the inventive subject matter optionally may include an additional element comprising an oil from Oncorhynchus species. Further, said compositions may be employed to treat a variety of diseases, disorders, and conditions, as described herein.

Abstract: A receptor for an insulin-like polypeptide is purified from yeast membranes. This "insulin receptor-like protein" has a structure analogous to that of the mammalian insulin receptor. The insulin receptor-like protein of Saccharomyces cerevisiae is a heterotetrameric glycoprotein. The protein has two polypeptide types, a first polypeptide which binds insulin and has an apparent molecular weight of 135,000 to 145,000 daltons and a second polypeptide which has an apparent molecular weight of 90,000 to 95,000 daltons and is phosphorylated on tyrosine in response to binding of insulin by said first polypeptide. The first and second polypeptides are joined by disulfide linkage. The protein requires a divalent metal ion for tyrosine autophosphorylation in response to binding of insulin. The yeast insulin receptor-like protein binds human insulin with a dissociation constant of K.sub.d =8.times.10.sup.-10 M and binds human insulin-like growth factor 1 with a K.sub.d =4.times.10.sup.-10 M.

Abstract: A purified insulin-like protein (ILP) isolated from Saccharomyces cerevisiae is disclosed. The ILP has a molecular weight of approximately 6.4 kilodaltons and the amino acid sequence of the 22 amino terminal residues of the protein has been determined. Computer-assisted molecular graphics analysis of ILP illustrates the similarity of the sequenced portion to vertebrate insulin A-chains.

Abstract: A receptor for an insulin-like polypeptide is purified from yeast membranes. This "insulin receptor-like protein" has a structure analogous to that of the mammalian insulin receptor. The insulin receptor-like protein of Saccharomyces cerevisiae is a heterotetrameric glycoprotein. The protein has two polypeptide types, a first polypeptide which binds insulin and has an apparent molecular weight of 135,000 to 145,000 daltons and a second polypeptide which has an apparent molecular weight of 90,000 to 95,000 daltons and is phosphorylated on tyrosine in response to binding of insulin by said first polypeptide. The first and second polypeptides are joined by disulfide linkage. The protein requires a divalent metal ion for tyrosine autophosphorylation in response to binding of insulin. The yeast insulin receptor-like protein binds human insulin with a dissociation constant of K.sub.d =8.times.10.sup.-10 M and binds human insulin-like growth factor 1 with a K.sub.d =4.times.10.sup.-10 M.